Novasep lays out $39M for new API plant

Novasep is continuing to expand its contract manufacturing capabilities, now spending $38.8 million to build a commercial API plant in Mourenx, France.

The facility is set to be up and running in 18 months, and it will be the largest pharmaceutical chromatography plant in the world once it's operational, Novasep says. The facility is designed to produce highly purified API, using in-house technology Novasep says can recycle 99.9% of the solvents it uses, making for an efficient and sustainable process.

"Demand for Novasep's advanced, purification-based manufacturing capabilities in the life science industries continues to increase as drugs in development and reaching the market become more complex and specific," CEO Patrick Glaser said in a statement.

Novasep has been spending big on international growth this year, drawing $53 million from a recapitalization fund to expand around the globe, including adding on to its Shanghai purification operation and spending $3.7 million on its French highly potent API plant over the summer.

- here's Novasep's release
- check out FiercePharmaManufacturing's take

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

The CRO will transfer most of its Pennsylvania-based biologics laboratory functions to a new, 73,000-square-foot site on Devon Park in Wayne.

Monoclonal antibodies developer Xencor extended a strategic alliance formed in 2016 with Selexis with four commercial license agreements.